

SINGLE SPECIES

In their response mailed December 18, 2001, Applicants elected the species of Formula (1.3.0):

Which is set out on page 71 of the instant specification. The elected species of Formula (1.3.0) falls within the scope of present Claim 1 that is a compound of Formula (IA); where R is $-(CH_2)_n(C_3-C_{10})$ cycloalkyl where n is 0 and that is a C_6 cycloalkyl group; R^1 is (C_1-C_9) alkyl that is a C_2 alkyl group; R^2 is hydrogen and R^2 comprises (-I-) that is a moiety of partial Formula (1.0.0):

where m is 0, R¹¹³ is cyano, R¹¹⁴ is H, and R¹¹⁵ is C(=0)OR¹¹⁹ where R¹¹⁹ is H.

The remaining claims that read on the elected species are as follows: Claims 2, 7-11, 16-20, 25-31, and 36-41. In Claims 10 and 39 the elected species is the fifth recited species in each said claim, i.e., "Cis-4-cyano-4-(1-cyclopentyl-3-ethyl-1*H*-indazol-6-yl)cyclohexanecarboxylic acid".

SINGLE AUXILIARY THERAPEUTIC AGENT

In their response mailed December 18, 2001, Applicants elected as the single auxiliary therapeutic agent, the species set forth in Claims 28 and 29 which is a proteinaceous synthetic opioid analgesic comprising an enkephalin consisting of [D-Ala²,MePhe⁴,-Gly(ot)⁵]enkephalin (DAMGO). In Claim 28 proteinaceous synthetic opioid analgesics are included in the group set forth as "(4)". Applicants make the clarification, accordingly, that they have elected as the subgenus of auxiliary therapeutic agents, group (4) in Claim 28, *i.e.*, "proteinaceous endogenous and synthetic opioid analgesics comprising enkephalins, endorphins, and dynorphins, which are selective and nonselective agonists and antagonists of the μ , κ , and δ opioid receptor subtypes".

The species of auxiliary therapeutic agent that Applicants have elected, as recited above, is "[D-Ala²,MePhe⁴,-Gly(ol)⁵]enkephalin (DAMGO)", which is a member of a Markush group recited in Claim 29 under the group set forth as "(4)" discussed above.

Consequently, Claims 28 and 29 read on the elected single auxiliary therapeutic agent.

SINGLE THERAPEUTIC AGENT

In their response mailed December 18, 2001, Applicants elected as the single therapeutic agent, the species recited in Claims 40 and 41 which is verapamil, under component (iii). However,



Applicants have herein canceled Claims 40 and 41, whereby the Examiner's requirement of election has been obviated.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: Julie 12, 2002

Raymond M. Speer Attorney for Applicants Reg. No. 26,810

Pfizer Inc Patent Department, 150-5-49 235 East 42nd Street New York, NY 10017-5755 (212) 733-4606